Valuation : Sensorion

Market Cap 129M 150M 121M 110M 207M 14.13B 207M 1.44B 554M 7.25B 562M 549M 23.06B P/E 2026 *
-33.3x
P/E 2027 * -5.56x
Enterprise Value -3.32M -3.86M -3.12M -2.85M -5.33M -365M -5.35M -37.03M -14.3M -187M -14.49M -14.17M -595M EV / Sales 2026 *
-0.15x
EV / Sales 2027 * 20.1x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
1 day+0.60%
1 week-8.09%
Current month-7.06%
1 month-12.13%
3 months-33.77%
6 months-37.97%
Current year-25.82%
1 week 0.24
Extreme 0.238
0.27
1 month 0.24
Extreme 0.238
0.3
Current year 0.22
Extreme 0.222
0.81
1 year 0.22
Extreme 0.222
0.81
3 years 0.15
Extreme 0.1544
1.04
5 years 0.15
Extreme 0.1544
2.29
10 years 0.15
Extreme 0.1544
7.74
Manager TitleAgeSince
Chief Executive Officer 59 01/06/2026
Director of Finance/CFO - 26/06/2024
Chief Tech/Sci/R&D Officer - 11/12/2023
Director TitleAgeSince
Director/Board Member - 09/03/2015
Director/Board Member 43 -
Chairman 61 30/03/2023
Date Insider Type Main position Quantity % Market Cap. Importance
2/6/26 A
Redmile Biopharma Investments III LP
BuyCompany 18,928,571 6.2956%
1/31/26 A
Sofinnova Partners SAS
BuyCompany 10,714,285 3.5636%
4/18/24 A
Redmile Biopharma Investments III LP
BuyCompany 2,781,914 1.0091%
Change 5-day change 1-year change 3-year change Capi.($)
+0.60%-8.09%-19.09%-64.08% 149M
-1.16%-3.97%-2.91%+13.00% 48.93B
-0.40%+1.03%+418.57%+527.30% 45.01B
-1.42%+2.30%+42.67%+22.37% 44.07B
-1.22%-2.31%+4.82%+77.49% 40.73B
-0.96%-2.31%+15.75%+45.41% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+120.75% 16.5B
-1.54%-1.05%+12.16%+29.80% 14.67B
-1.65%-1.03%+75.93%+41.12% 13.77B
Average -0.83%-0.43%+63.26%+90.35% 27.51B
Weighted average by Cap. -1.00%+0.05%+88.89%+128.31%

Financials

2026 *2027 *
Net sales 21.86M 25.41M 20.56M 18.76M 35.09M 2.4B 35.2M 244M 94.13M 1.23B 95.42M 93.31M 3.92B 6.4M 7.43M 6.02M 5.49M 10.27M 702M 10.3M 71.32M 27.54M 360M 27.92M 27.3M 1.15B
Net income -237K -275K -223K -203K -380K -26M -381K -2.64M -1.02M -13.33M -1.03M -1.01M -42.42M -36.12M -41.99M -33.98M -31.01M -57.99M -3.97B -58.17M -403M -156M -2.03B -158M -154M -6.47B
Net Debt -132M -153M -124M -113M -212M -14.5B -213M -1.47B -568M -7.43B -576M -563M -23.66B -
Logo Sensorion
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
63
Date Price Change Volume
07/09/26 €0.2500 +0.60% 565,108
04/09/26 €0.2485 -2.93% 1,206,346
03/09/26 €0.2560 -0.39% 1,181,678
02/09/26 €0.2570 -3.38% 644,753
01/09/26 €0.2660 -1.12% 440,527
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2500EUR
Average target price
1.138EUR
Spread / Average Target
+355.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALSEN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!